Primary, Fully Characterized autologous AML System allows the correlation of T Cell Activation with Leukemia Cell survival upon IO treatment in a novel autologous system

Acute myeloid leukemia (AML) is a complex malignancy developing in the bone marrow leading to challenges in the clinic.
In the clinical and pre-clinical settings, accurate classification of AML patients is essential for the proper model classification which enables researchers to study specific AML subtypes, providing insights into potential mechanisms and therapeutic targets (1).

The main limitation in developing effective immunotherapy is due to both, the lack of relevant translational models where immune cells are representative of the actual disease, and the intrinsic AML heterogeneity further complicating the translation of findings into effective immunotherapy.

In AML patients, the bone marrow microenvironment induces immunosuppression leading to immune escape therefore impacting our ability to unlock immune cells surveillance (2). Thus, it is key to adopt well-characterized pre-clinical models entirely derived from primary patients’ samples that harbor the autologous immune cells and closely recapitulate the diseased microenvironment.